EFFICACY AND SAFETY OF USTEKINUMAB IN ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A SUBPOPULATION ANALYSIS OF UNITI/IM-UNITI LONG-TERM EXTENSION THROUGH 5 YEARS

Toshifumi Hibi  1     Christopher Gasink  2     Yuya Imai  3     Carine Saadoun  4     Jianmin Zhuo  5     Shiho Kawamura  5    
1 Kitasato University, Tokyo, Japan
2 Janssen Scientific Affairs, LLC, Horsham, United States
3 Janssen Pharmaceutical K.K., Tokyo, Japan
4 Janssen Pharmaceuticals Asia Pacific, Singapore, Singapore
5 Janssen China Research & Development, Shanghai

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing